GSK has enlisted the aid of basketball legend Magic Johnson to front an awareness campaign on the dangers of respiratory syncytial virus (RSV) as it prepares for an FDA de
The race to market for a next-generation meningococcal vaccine has gone up a gear once again, with GSK reporting phase 3 results in support of its five-in-one candidate, a
Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs
The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one.
Construction will start early next year on a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance betwee
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough